Oncology

Follow-up data reveal 10-year impact of ibrutinib in treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

Pharmacists can also play a role in SDOH by replacing drug delivery with something else, such as food or transportation delivery, according to speakers at the ATOPP conference.

The European Union (EU) has successfully created a competitive market for biosimilars, while the US faces challenging market dynamics and tactics by pharmacy benefit managers that hinder the adoption of lower-cost therapies.

Collaboration between community centers and academic medical centers can improve patient access to these complex therapies.

Combining multiple drugs to induce a deep response in patients with diffuse large B-cell lymphoma could open curative pathways for those affected.

An increased frequency of immunoglobulin G testing in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) was also associated with a lower likelihood of severe infections.

Antibody drug conjugate TUB-040 demonstrated superior biophysical properties for treating platinum-resistant ovarian cancer.

Health professionals have expressed concerns regarding consistent naming standards, the regulatory process surrounding the approval of biosimilar drugs, and the lack of education they have about biosimilars.

When treating patients with graft-vs-host disease, pharmacists are often responsible for selecting treatment regimens while navigating other spheres of care.

Laura Bray, founder of Angels for Change, explains that addressing the 4 key economic causes to drug shortages can also help lead to effective solutions long-term.

A biologics license application (BLA) for patritumab deruxtecan receives complete response letter due to inspection findings at third-party manufacturer.

HOPA’s DEI Advisory Board Chair discusses how creating safe environments, using correct pronouns, and being willing to talk about patients’ mental and physical needs are significant when providing care to LGBTQIA+ patients.

The approval marks the first and only T-cell engaging bispecific antibody administered subcutaneously to treat patients after 2 or more lines of systemic therapy.

Site-of-care considerations can pose challenges with these therapies.

Heidi Finnes, PharmD, BCOP, FHOPA, discusses the evolving landscape of treatment for patients with cutaneous malignancies and melanoma.

Oncology pharmacists can help normalize and encourage SOGI data collection.

Rose DiMarco, PharmD, BCPS, BCOP, shares insights into the evolving treatment landscape for patients with breast cancer with specific mutations.

An interdisciplinary discussion addresses the disparity in availability and use of these therapies across the continuum of care.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses the crucial role pharmacists play in providing supportive care for patients with cancer.

Jordyn P. Higgins, PharmD, BCOP, discusses the evolving treatment landscape for small cell lung cancer (SCLC).

Adagrasib receives accelerated approval for patients with previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC).

Questions arise around equity and revenue challenges.

The quadruplet regimen added bortezomib to the current standard of care, which is a triplet regimen of isatuximab, lenalidomide, and dexamethasone for patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM TI).

There are numerous challenges with cell and gene therapies in oncology, such as accessibility, cost, and prior authorizations, as well as the need for improved education and training within the oncology community.

Tim Mok, PharmD, BCOP, BCPS, discusses innovative therapies that are changing the treatment options available for patients with hematologic malignancies.

Fostering communication and shared terminology is key.

Ryan Haumschild discusses the evolving treatment landscape for patients with multiple myeloma.

Additionally, the high cost of the cell therapy raises concerns for broader access.

Compared with standard of care chemoimmunotherapy, acalabrutinib with bendamustine and rituximab reduced risk of death or disease by approximately 27%.

Participants in the study had durable response for over 1 year, in addition to positive efficacy indicators.